Bill Gross warns on gold momentum as regional bank stocks tumble
Supernus Pharmaceuticals Inc. (SUPN) stock has reached a new 52-week high, climbing to 48.47 USD. According to InvestingPro data, the company maintains impressive gross profit margins of 88.5% and boasts a healthy current ratio of 2.58, indicating strong financial stability. This milestone marks a significant achievement for the $2.7 billion market cap company, reflecting a robust performance over the past year. The stock’s ascent to this 52-week high comes amidst a notable 1-year change, with the company’s shares appreciating by 50.65%. This impressive growth underscores the market’s confidence in Supernus Pharmaceuticals’ prospects and its strategic initiatives. Investors have shown increased interest, driving the stock price to this new peak, as the company continues to make strides in its sector. InvestingPro analysis reveals 12 additional key insights about SUPN’s financial health and market position, available in the comprehensive Pro Research Report.
In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, achieving a revenue of $165 million, which exceeded the forecast of $154.3 million. However, the company’s earnings per share (EPS) were $0.40, missing the projected $0.48. The revenue growth was largely attributed to the strong performance of Supernus’s products, Qelbree and Gocovri. In light of these developments, several analyst firms have adjusted their price targets for the company. Cantor Fitzgerald raised its price target to $63.00, citing a faster-than-expected adoption rate of ONAPGO. Piper Sandler increased its target to $40.00, noting the strong launch performance of ONAPGO as a potential upside. Stifel also raised its price target to $43.00, acknowledging the company’s strong second-quarter performance. These adjustments reflect the analysts’ revised outlooks based on the company’s recent achievements and product performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.